RESUMEN

The malignant potential of oral lichen planus (OLP) has been discussed and disputed for decades. The lesions are often characterized by strong expression of the TP53 protein in the basal layer of the mucosa. In 2002, we reported the presence of TP53 mutations in nine out of 27 OLP lesions tested. At follow-up in 2009, one case of oral squamous cell cancer (OSCC) had occurred in a different site six years later. In contrast, in another case, TP53 mutation persisted for years without malignant transformation. In a longitudinal study of eight selected patients with OSCC or different pre-malignant lesions, it was concluded that TP53 mutations could occur early or late in the development of OSCC. A follow-up in the present, almost 20 years later, revealed that one further case of OSCC had occurred in a TP53-mutated case of OLP, 21 years after the first sample was taken, again in a different site. With this second case, this small study now points towards a risk of developing OSCC in TP53-mutated OLP lesions. A review of recent literature indicates a growing consensus that OLP should be regarded as a potentially pre-malignant lesion. Several protein markers have been studied, but none proved useful for prediction of malignant progression. The great majority of published studies are retrospective, and it has been suggested that multi-centre prospective studies will be needed to reach a definitive answer on the malignant potential of OLP, and particularly, to identify contributing factors. Screening for TP53 mutations could help to identify the subgroup of OLP patients that is truly at risk of developing oral cancer.

RESUMEN

The oral and dental health of patients with Parkinson's disease (PD) has not been well documented and the findings are conflicting. Patients with PD were invited to take part in a clinical and radiographic examination together with a comparison control group of persons who were a spouse or family member. Subjects (n = 67) and controls (n = 55) were examined and compared. Subjects with PD had more missing teeth, caries, dental plaque, and poorer periodontal health. Counts of cariogenic bacteria in saliva were significantly higher for subjects with PD. They did not consume more sweets or sugar, did not brush less frequently, used dental floss more than controls, and visited the dentist at least as often. Salivary flow levels were comparable between subjects with PD and controls. The lack of muscular control may explain the poorer oral health of patients with PD. Dentists and patients with PD may be reluctant to embark on complex dental procedures, and this may explain the increased number of missing teeth in persons with PD in this study.

Asunto(s)

RESUMEN

OBJECTIVE: Aphthous ulceration is a common form of recurrent ulceration of the oral mucosa. Numerous treatments have been tried as a means of relieving pain, disinfecting the ulcer base, and reducing inflammation, but with limited success. Tetracycline and its derivatives have been shown to be inhibitors of matrix metalloproteinases (MMPs), which are part of the inflammatory response and contribute to the breakdown of tissue in the ulcer. Of the commercially available tetracyclines, doxycycline has shown the best inhibition of the MMPs. The aim of this study was to test clinically whether the inhibitory effect of a low-dose doxycycline in a hydrogel on MMPs would speed the recovery of oral ulceration. MATERIAL AND METHODS: Forty-nine patients participated in a randomized, double-blind, placebo-controlled trial. RESULTS: Sixty-eight percent of ulcers had healed by the third day of treatment with the doxycycline gel, whereas only 25% of the patients receiving the placebo reported healing of their ulcers within 3 days. Patients treated with the docycline gel recounted faster reduction in pain during the treatment period than the placebo group did. CONCLUSIONS: Incorporation of low-dose doxycycline in a muco-adhesive gel has been demonstrated to have potential in the treatment of recurrent oral ulceration. It is concluded that MMP enzymes can be inhibited by low doses of doxycycline below levels likely to disrupt the oral flora.

Asunto(s)